Suprachoroidal Space TA Formulation Advances in Clinical Trials
A proprietary form of triamcinolone acetonide for injection into the suprachoroidal space (CLA-TA; Clearside Biomedical) for the treatment of noninfectious uveitis met primary and secondary endpoints in the Dogwood clinical trial, according to a company press release of top-line data. Clearside also announced updates on the enrollment status of the Peachtree and Tanzanite trials, both of which will assess the safety and efficacy of CLA-TA in ocular diseases.
In the Dogwood trial, a single suprachoroidal microinjection of CLA-TA resulted in reduction of central subfield thickness (P = .0018) and mean improvement from baseline in BCVA (P = .0004) at 8 weeks. There were no serious adverse events related to the treatment in the trial, including no increases in IOP.
The Peachtree trial, a phase 3 trial assessing CLA-TA in the suprachoroidal space for the treatment of macular edema associated with noninfectious uveitis, has enrolled its first patient. The Tanzanite trial, a phase 2 clinical trial assessing the safety and efficacy of CLS-TA in the suprachoroidal space combined with intravitreal aflibercept (Eylea, Regeneron) for treatment of macular edema associated with retinal vein occlusion, has completed enrollment.